1. Home
  2. INTZ vs NEUP Comparison

INTZ vs NEUP Comparison

Compare INTZ & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intrusion Inc.

INTZ

Intrusion Inc.

N/A

Current Price

$0.41

Market Cap

13.1M

ML Signal

N/A

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$2.55

Market Cap

14.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
INTZ
NEUP
Founded
1983
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Sector
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
13.1M
14.9M
IPO Year
2020
2002

Fundamental Metrics

Financial Performance
Metric
INTZ
NEUP
Price
$0.41
$2.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 173.6K
32.8K
Earning Date
11-12-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 71.78
N/A
EPS
★ N/A
N/A
Revenue
★ $7,015,000.00
$1,174,165.00
Revenue This Year
$22.62
N/A
Revenue Next Year
$26.44
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 21.56
N/A
52 Week Low
$0.47
$2.54
52 Week High
$1.56
$5.53

Technical Indicators

Market Signals
Indicator
INTZ
NEUP
Relative Strength Index (RSI) 34.65 16.20
Support Level N/A N/A
Resistance Level $0.89 $4.15
Average True Range (ATR) 0.08 0.14
MACD -0.01 -0.04
Stochastic Oscillator 3.15 2.11

Price Performance

Historical Comparison
INTZ
NEUP

About INTZ Intrusion Inc.

Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.

Share on Social Networks: